Marizyme (OTC: MRZM), a client of Univest Securities LLC, a full-service investment bank and securities broker-dealer firm and a member of FINRA and SIPC, recently closed the acquisition of Somahlution Inc. and a private placement for $7,000,240 to which Univest Securities acted as the exclusive investment bank and sole-placement agent. According to the update, the Marizyme acquisition of Somahlution Inc. included all of Somahlution LLC’s assets including its DuraGraft(R) intellectual property, Somaceutica intellectual property and derivative works. In addition, Univest Securities raised a total of $7,000,240 in gross proceeds in a private placement offering with common shares only for Marizyme, with a total of 5,600,192 shares each sold at an offering price of $1.25. Marizyme plans to use the proceeds to expand sales of DuraGraft in Europe and to begin to seek U.S. FDA approval. “We are excited to complete this transaction and most importantly bring on the seasoned technical leadership of the Somahlution’s team,” Marizyme’s Executive Chairman James Sapirstein said in the press release. “In addition, we are grateful to Univest Securities and our new investors for the trust they are placing in us to deliver strong shareholder value for Marizyme. Somahlution’s platform technology has enabled the development of a robust product pipeline with the potential to address unmet medical needs and reduce disease burden not only in vascular grafting indications but also indications involving tissue and fat grafting and organ transplant. DuraGraft protects graft tissue from harvesting through anastomosis and is used as a treatment to maintain the structural and functional integrity of free vascular grafts. The use of DuraGraft is associated with reductions of post-CABG complications associated with graft disease and failure: Myocardial Infarction, Repeat Revascularization and other Major Adverse Cardiac Events.”
To view the full press release, visit https://nnw.fm/IClgI
About Marizyme Inc.
Marizyme is a development-stage company dedicated to the commercialization of innovative therapies that address the urgent unmet needs relating to higher mortality and costs in the acute care space. Specifically, Marizyme will focus its efforts on expanding the applications for its technologies to dental care, wound healing, thrombosis and other tissue preserving uses. For more information, visit www.Marizyme.com or www.Somahlution.com.
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.networknewswire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork
